Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,419
archived clinical trials in
Pulmonary

PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Pensacola, FL
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Pensacola, FL
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Stockbridge, GA
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Stockbridge, GA
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Minneapolis, MN
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Brooklyn, NY
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Charlotte, NC
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Winston-Salem, NC
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Cincinnati, OH
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Medford, OR
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Medford, OR
Click here to add this to my saved trials
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated:  4/26/2017
Pearl Investigative Site
mi
from
Spartanburg, SC
PT003 MDI Dose Confirmation Study
A Randomized, Double Blind, Chronic Dosing (7 Days), Two Period, Six Treatment, Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Four Doses of PT003 MDI in Patients With Moderate to Severe COPD, Compared With Its Individual Components (PT005 MDI and PT001 MDI) as Active Controls
Status: Enrolling
Updated: 4/26/2017
Pearl Investigative Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies
Prematurity and Respiratory Outcome Program: Single Center Study of Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies
Status: Enrolling
Updated:  5/2/2017
Women and Children's Hospital of Buffalo
mi
from
Buffalo, NY
Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies
Prematurity and Respiratory Outcome Program: Single Center Study of Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies
Status: Enrolling
Updated: 5/2/2017
Women and Children's Hospital of Buffalo
mi
from
Buffalo, NY
Click here to add this to my saved trials
Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies
Prematurity and Respiratory Outcome Program: Single Center Study of Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies
Status: Enrolling
Updated:  5/2/2017
Univ of Rochester Medical Center
mi
from
Rochester, NY
Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies
Prematurity and Respiratory Outcome Program: Single Center Study of Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies
Status: Enrolling
Updated: 5/2/2017
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Psychopharmacology for Cocaine Dependence - Buspirone
Psychopharmacology of Novel Medications for Cocaine Dependence - Buspirone
Status: Enrolling
Updated:  5/3/2017
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Psychopharmacology for Cocaine Dependence - Buspirone
Psychopharmacology of Novel Medications for Cocaine Dependence - Buspirone
Status: Enrolling
Updated: 5/3/2017
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Citalopram for Cocaine Dependence
Clinical Trial of Serotonin Medication Combination in Cocaine Dependence
Status: Enrolling
Updated:  5/3/2017
UT-Houston Behavioral and Biomedical Sciences Building
mi
from
Houston, TX
Citalopram for Cocaine Dependence
Clinical Trial of Serotonin Medication Combination in Cocaine Dependence
Status: Enrolling
Updated: 5/3/2017
UT-Houston Behavioral and Biomedical Sciences Building
mi
from
Houston, TX
Click here to add this to my saved trials
Postoperative Respiratory Monitoring After Neuraxial Opioid Administration for Cesarean Delivery
Postoperative Respiratory Monitoring After Neuraxial Opioid Administration for Cesarean Delivery
Status: Enrolling
Updated:  5/3/2017
Lucile Packard Children's Hospital
mi
from
Palo Alto, CA
Postoperative Respiratory Monitoring After Neuraxial Opioid Administration for Cesarean Delivery
Postoperative Respiratory Monitoring After Neuraxial Opioid Administration for Cesarean Delivery
Status: Enrolling
Updated: 5/3/2017
Lucile Packard Children's Hospital
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Herpesvirus in Idiopathic Pulmonary Fibrosis
Herpesvirus in Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated:  5/10/2017
Emory University
mi
from
Atlanta, GA
Herpesvirus in Idiopathic Pulmonary Fibrosis
Herpesvirus in Idiopathic Pulmonary Fibrosis
Status: Enrolling
Updated: 5/10/2017
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of Tobacco Smoke and Children With Respiratory Illnesses
Urine Cotinine in Children and Parental Behavior Modification: A Pilot Study
Status: Enrolling
Updated:  5/15/2017
The Barbara Bush Children's Hospital at Maine Medical Center
mi
from
Portland, ME
A Study of Tobacco Smoke and Children With Respiratory Illnesses
Urine Cotinine in Children and Parental Behavior Modification: A Pilot Study
Status: Enrolling
Updated: 5/15/2017
The Barbara Bush Children's Hospital at Maine Medical Center
mi
from
Portland, ME
Click here to add this to my saved trials
Effects of Treating Sleep Apnea in Patients With Congestive Heart Failure
Effects of Treating Sleep Apnea in Patients With Congestive Heart Failure
Status: Enrolling
Updated:  5/16/2017
University of Florida
mi
from
Gainesville, FL
Effects of Treating Sleep Apnea in Patients With Congestive Heart Failure
Effects of Treating Sleep Apnea in Patients With Congestive Heart Failure
Status: Enrolling
Updated: 5/16/2017
University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients
Status: Enrolling
Updated:  5/18/2017
Amphastar Site 2
mi
from
Medford, OR
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients
Status: Enrolling
Updated: 5/18/2017
Amphastar Site 2
mi
from
Medford, OR
Click here to add this to my saved trials
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients
Status: Enrolling
Updated:  5/18/2017
Amphastar Site 1
mi
from
Portland, OR
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients
Status: Enrolling
Updated: 5/18/2017
Amphastar Site 1
mi
from
Portland, OR
Click here to add this to my saved trials
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients
Status: Enrolling
Updated:  5/18/2017
Amphastar Site 6
mi
from
San Antonio, TX
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients
Status: Enrolling
Updated: 5/18/2017
Amphastar Site 6
mi
from
San Antonio, TX
Click here to add this to my saved trials
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients
Status: Enrolling
Updated:  5/18/2017
Amphastar Site 0034
mi
from
Seattle, WA
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
A Randomized, Double- or Evaluator-blinded, Active- and Placebo-controlled, Cumulative-dose, Dose-escalating, Three-arm, Cross-over Study, in 24 Asthma Patients
Status: Enrolling
Updated: 5/18/2017
Amphastar Site 0034
mi
from
Seattle, WA
Click here to add this to my saved trials
Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases
Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases
Status: Enrolling
Updated:  5/23/2017
Weill Medical College of Cornell University
mi
from
New York, NY
Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases
Collection of Blood for Gene Expression Study in Individuals With Chronic Lung Diseases
Status: Enrolling
Updated: 5/23/2017
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Phoenix, AZ
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Palo Alto, CA
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Largo, FL
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Largo, FL
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Chicago, IL
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Baltimore, MD
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Ann Arbor, MI
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Rochester, MN
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Chesterfield, MO
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Chesterfield, MO
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Sites
mi
from
Summit, NJ
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Sites
mi
from
Summit, NJ
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
New York, NY
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Charlotte, NC
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Greensboro, NC
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Greensboro, NC
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Tulsa, OK
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Rock Hill, SC
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Rock Hill, SC
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Nashville, TN
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Salt Lake City, UT
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Falls Church, VA
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Falls Church, VA
Click here to add this to my saved trials
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated:  5/30/2017
Afferent Investigative Site
mi
from
Seattle, WA
A Study of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016)
A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough
Status: Enrolling
Updated: 5/30/2017
Afferent Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Cardiovascular Disease and Obstructive Sleep Apnea
Pharmacologic Interventions for Cardiovascular Disease in Obstructive Sleep Apnea
Status: Enrolling
Updated:  6/1/2017
Aurora Bay Care
mi
from
Green Bay, WI
Study of Cardiovascular Disease and Obstructive Sleep Apnea
Pharmacologic Interventions for Cardiovascular Disease in Obstructive Sleep Apnea
Status: Enrolling
Updated: 6/1/2017
Aurora Bay Care
mi
from
Green Bay, WI
Click here to add this to my saved trials
Study of Cardiovascular Disease and Obstructive Sleep Apnea
Pharmacologic Interventions for Cardiovascular Disease in Obstructive Sleep Apnea
Status: Enrolling
Updated:  6/1/2017
University of Wisconsin-Madison
mi
from
Madison, WI
Study of Cardiovascular Disease and Obstructive Sleep Apnea
Pharmacologic Interventions for Cardiovascular Disease in Obstructive Sleep Apnea
Status: Enrolling
Updated: 6/1/2017
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Study of Cardiovascular Disease and Obstructive Sleep Apnea
Pharmacologic Interventions for Cardiovascular Disease in Obstructive Sleep Apnea
Status: Enrolling
Updated:  6/1/2017
Marshfield Clinic
mi
from
Marshfield, WI
Study of Cardiovascular Disease and Obstructive Sleep Apnea
Pharmacologic Interventions for Cardiovascular Disease in Obstructive Sleep Apnea
Status: Enrolling
Updated: 6/1/2017
Marshfield Clinic
mi
from
Marshfield, WI
Click here to add this to my saved trials
Study of Cardiovascular Disease and Obstructive Sleep Apnea
Pharmacologic Interventions for Cardiovascular Disease in Obstructive Sleep Apnea
Status: Enrolling
Updated:  6/1/2017
Gundersen Lutheran
mi
from
La Crosse, WI
Study of Cardiovascular Disease and Obstructive Sleep Apnea
Pharmacologic Interventions for Cardiovascular Disease in Obstructive Sleep Apnea
Status: Enrolling
Updated: 6/1/2017
Gundersen Lutheran
mi
from
La Crosse, WI
Click here to add this to my saved trials
Obstructive Sleep Apnea and Metabolic Health
Obstrutive Sleep Apnea: is it a Biomarker of Metabolically Healthy vs. Unhealthy Obese
Status: Enrolling
Updated:  6/6/2017
Ohio State University
mi
from
Columbus, OH
Obstructive Sleep Apnea and Metabolic Health
Obstrutive Sleep Apnea: is it a Biomarker of Metabolically Healthy vs. Unhealthy Obese
Status: Enrolling
Updated: 6/6/2017
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George¿s Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months
Status: Enrolling
Updated:  6/7/2017
205.452.01199 Boehringer Ingelheim Investigational Site
mi
from
Danbury, CT
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George¿s Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months
Status: Enrolling
Updated: 6/7/2017
205.452.01199 Boehringer Ingelheim Investigational Site
mi
from
Danbury, CT
Click here to add this to my saved trials
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George¿s Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months
Status: Enrolling
Updated:  6/7/2017
205.452.01251 Boehringer Ingelheim Investigational Site
mi
from
Sarasota, FL
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George¿s Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months
Status: Enrolling
Updated: 6/7/2017
205.452.01251 Boehringer Ingelheim Investigational Site
mi
from
Sarasota, FL
Click here to add this to my saved trials
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George¿s Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months
Status: Enrolling
Updated:  6/7/2017
1199.14.1261 Boehringer Ingelheim Investigational Site
mi
from
Skokie, IL
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George¿s Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months
Status: Enrolling
Updated: 6/7/2017
1199.14.1261 Boehringer Ingelheim Investigational Site
mi
from
Skokie, IL
Click here to add this to my saved trials
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George¿s Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months
Status: Enrolling
Updated:  6/7/2017
1245.23.10148 Boehringer Ingelheim Investigational Site
mi
from
Lexington, KY
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George¿s Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months
Status: Enrolling
Updated: 6/7/2017
1245.23.10148 Boehringer Ingelheim Investigational Site
mi
from
Lexington, KY
Click here to add this to my saved trials
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George¿s Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months
Status: Enrolling
Updated:  6/7/2017
1199.15.10103 Boehringer Ingelheim Investigational Site
mi
from
Minneapolis, MN
Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)
A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George¿s Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months
Status: Enrolling
Updated: 6/7/2017
1199.15.10103 Boehringer Ingelheim Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials